Therapy Areas: Central Nervous System
Alora Pharmaceuticals announces Relexxii commercial launch
20 December 2023 -

Alora Pharmaceuticals LLC, the US-based parent company of Vertical Pharmaceuticals, LLC, announced on Tuesday that it has commercially launched Relexxii (methylphenidate hydrochloride extended-release tablets).

Relexxii, a once-daily central nervous system (CNS) stimulant, is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and in paediatric patients six years of age and older. The company says that with the product's launch, patients and health care professionals will have an additional branded ADHD treatment option from which to select.

Once-daily Relexxii is now widely available in flexible dosing options and is claimed to support a more tailored treatment approach throughout the ADHD treatment journey: 18-mg, 27-mg, 36-mg, 45-mg, 54-mg, 63-mg and 72-mg. This line of once-daily strengths has been specifically designed to support targeted titration to help achieve the lowest effective dose and to help mitigate the need for multiple daily pills. Once-daily Relexxii strengths are offered in 9-mg increments, yielding two 'in-between' doses of 45-mg and 63-mg.

Relexxii once-daily dosing is made possible by Alora Pharmaceutical's Osmodex Drug Delivery Technology, which allows the medication to be released at a controlled rate throughout the day.